Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB

Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB

As the trading week approaches, now is an opportune moment for investors to delve deeper into companies garnering recent attention. This feature will offer insights into five such stocks. 

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) has shown robust performance recently, accompanied by a significant increase in trading volume. Since March 20, the stock has surged by 121% and closed at $2.95 per share on April 11, driven by a prolonged short squeeze. On March 27, the company released its financial results for the fiscal year ending January 31, 2024. Quarterly revenues rose to $3.2 million from $2.5 million in the corresponding period last year, mainly due to reduced credits issued to customers. The net loss for the quarter was $2.2 million, marking a decrease from the previous year's net loss of $3 million. 

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a key player in the medical technology sector, specializes in providing fast, non-invasive, and intelligent testing solutions. Ladenburg Thalmann, a well-known Wall Street institution established in 1876, issued a buy recommendation for Intelligent Bio Solutions Inc. stock, setting a target price of $12 per share. Furthermore, on March 11, the company announced raising $10.1 million through a private placement involving accredited investors in the healthcare sector and institutional investors. On April 11, the company expanded the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, by securing a new European patent with unitary effect for its innovative DSR-Plus Cartridge Reader. 

General Enterprise Ventures Inc. (OTC: GEVI) gained recognition primarily for the advancements made by its subsidiary, Mighty Fire Breaker LLC (MFB), in the field of fire-retardant solutions. In April, it was revealed that Joshua Robinson, the Chief Executive Officer of General Enterprise Ventures Inc., had returned 60% of the company’s outstanding common stock shares to the Treasury, a move expected to significantly enhance shareholder value. On April 2, news surfaced about a collaboration between SkyScout Ai Innovations and MFB's Value-Add Wildfire Reduction Team, signaling MFB's entry into the Canadian market with its fire-retardant product CitroTech. 

Catheter Precision Inc. (NYSE American: VTAK) was highlighted in a Ladenburg Thalmann research report on April 5, 2023, with a buy recommendation and a $4 target price for the next year. On April 1, the company reported its Q4 and full fiscal year results for 2023, showing total assets of $30.7 million, a cash balance of $3.6 million, and notable revenue growth compared to the previous year. The company also reduced its net loss in the fourth quarter to $0.7 million from $8.2 million. Additionally, on April 4, Catheter Precision expanded its business development team with industry professionals to drive sales growth and market expansion. 

Rallybio Corporation (NASDAQ: RLYB) gained attention on April 10 following its announcement of a collaboration with Johnson & Johnson (NYSE: JNJ). Under the agreement, Rallybio Corporation will assist in developing complementary therapeutic methods to reduce the risk of FNAIT (fetal and neonatal alloimmune thrombocytopenia). Additionally, Johnson & Johnson Innovations invested $6.6 million in Rallybio Corporation as part of the collaboration.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.